Arbutus Biopharma (ABUS) Retained Earnings (2010 - 2026)
Arbutus Biopharma (ABUS) posted Retained Earnings of -$1.2 billion for Q1 2026, up 12.3% sequentially from -$1.4 billion in Q4 2025, and up 11.72% YoY from -$1.1 billion in Q1 2025.
Arbutus Biopharma (ABUS) Retained Earnings (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Retained Earnings for 17 years, with the latest figure at -$1.2 billion in Q1 2026.
- Quarterly Retained Earnings rose 11.72% year-over-year to -$1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (up 11.72% YoY) and the FY2025 annual result came in at -$1.4 billion, down 2.49% from the prior year.
- Retained Earnings grew to -$1.2 billion in Q1 2026 per ABUS's latest filing, from -$1.4 billion in the prior quarter.
- Over five years, Retained Earnings peaked at -$1.2 billion in Q1 2022 and troughed at -$1.4 billion in Q4 2025.
- A 5-year average of -$1.3 billion and a median of -$1.3 billion in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings declined 7.94% in 2022, then rose 11.72% in 2026.
- Over 5 years, Retained Earnings stood at -$1.2 billion in 2022, then declined by 6.05% to -$1.3 billion in 2023, then fell by 5.48% to -$1.3 billion in 2024, then declined by 2.49% to -$1.4 billion in 2025, then climbed by 12.3% to -$1.2 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.2 billion, -$1.4 billion, and -$1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -1.22 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.22 Bn |
| Mar 31, 2026 | -1.21 Bn |
| Dec 31, 2025 | -1.38 Bn |
| Sep 30, 2025 | -1.38 Bn |
| Jun 30, 2025 | -1.37 Bn |
| Mar 31, 2025 | -1.37 Bn |
| Dec 31, 2024 | -1.35 Bn |
| Sep 30, 2024 | -1.33 Bn |
| Jun 30, 2024 | -1.31 Bn |
| Mar 31, 2024 | -1.29 Bn |
| Dec 31, 2023 | -1.28 Bn |
| Sep 30, 2023 | -1.26 Bn |
| Jun 30, 2023 | -1.24 Bn |
| Mar 31, 2023 | -1.22 Bn |
| Dec 31, 2022 | -1.20 Bn |
| Sep 30, 2022 | -1.18 Bn |
| Jun 30, 2022 | -1.16 Bn |
| Mar 31, 2022 | -1.15 Bn |
| Dec 31, 2021 | -1.13 Bn |
| Sep 30, 2021 | -1.11 Bn |